The overall objective of this project continues to be the elucidation of the mechanism of action of morphine and other opiate analgesics. A secondary objective is to determine the role of endogenous opioid peptides in various respiratory diseases of children and infants. We have found that children who have apnea as a part of their symptomatology have an increased level of endogenous opioid peptide in their cerebrospinal fluid. We now propose to expand our preliminary results which show that naltrexone, an opiate antagonist, is efficacious in treatment of the disease in these children. We further will explore whether other endogenous opioid peptides, such as met-enkephalin, leu-enkephalin, and dynorphin, are also elevated and a causative factor in the disease of these patients. We will continue to develop an animal model for these diseases which will be essential to evaluate the etiology of the disease and mechanism of action of naltrexone. The second portion of this proposal has to do with our demonstration that the intrathecal injection of mice with morphine produces a pronounced hypoglycemia. This was a surprising observation, since morphine administered by any other route of administration produces hyperglycemia. We will continue to investigate the mechanisms of disappearance of glucose from the blood following the intrathecal injection of opiates. Thirdly, we propose to continue our investigation into the role of intracellular calcium in the mechanism of action of morphine. It has been shown by others and ourselves that morphine alters calcium homeostasis in both the drug-naive animal as well as in the opiate-tolerant animal. These investigations will continue. The work described in this proposal has both theoretical and practical applications. The calcium and glucose experiments will add greatly to our knowledge of the effects of morphine in living organisms, while our studies with the endogenous opioid peptides will be beneficial to the treatment of children with various diseases characterized at least in part by apnea.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA001647-17
Application #
3206982
Study Section
Special Emphasis Panel (SRCD (19))
Project Start
1976-12-01
Project End
1995-06-30
Budget Start
1993-07-01
Budget End
1994-06-30
Support Year
17
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
Schools of Medicine
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Bailey, C P; Oldfield, S; Llorente, J et al. (2009) Involvement of PKC alpha and G-protein-coupled receptor kinase 2 in agonist-selective desensitization of mu-opioid receptors in mature brain neurons. Br J Pharmacol 158:157-64
Bailey, C P; Llorente, J; Gabra, B H et al. (2009) Role of protein kinase C and mu-opioid receptor (MOPr) desensitization in tolerance to morphine in rat locus coeruleus neurons. Eur J Neurosci 29:307-18
Gabra, Bichoy H; Bailey, Chris P; Kelly, Eamonn et al. (2008) Pre-treatment with a PKC or PKA inhibitor prevents the development of morphine tolerance but not physical dependence in mice. Brain Res 1217:70-7
Haller, Victoria L; Bernstein, Marissa A; Welch, Sandra P (2008) Chronic morphine treatment decreases the Cav1.3 subunit of the L-type calcium channel. Eur J Pharmacol 578:101-7
Gabra, Bichoy H; Smith, Forrest L; Navarro, Hernan A et al. (2008) mGluR5 antagonists that block calcium mobilization in vitro also reverse (S)-3,5-DHPG-induced hyperalgesia and morphine antinociceptive tolerance in vivo. Brain Res 1187:58-66
Stoller, Dawn C; Sim-Selley, Laura J; Smith, Forrest L (2007) Role of kappa and delta opioid receptors in mediating morphine-induced antinociception in morphine-tolerant infant rats. Brain Res 1142:28-36
Smith, Forrest L; Lindsay, Raymond J (2007) Enhancement of bupivacaine local anesthesia with the potassium channel blocker ibutilide. Eur J Pain 11:551-6
Bailey, Chris P; Smith, Forrest L; Kelly, Eamonn et al. (2006) How important is protein kinase C in mu-opioid receptor desensitization and morphine tolerance? Trends Pharmacol Sci 27:558-65
Bernstein, M A; Welch, S P (1999) A method for the determination of activated receptor phosphorylation state following in vivo drug treatment. Brain Res Brain Res Protoc 4:420-4
Bernstein, M A; Welch, S P (1998) Inhibition of protein phosphatases alters the expression of morphine tolerance in mice. Eur J Pharmacol 341:173-7

Showing the most recent 10 out of 63 publications